NOTE: This site is for informational purposes only. While we make every effort to keep it up to date, there is no guarantee that information is complete, accurate, comprehensive, or the same for all KP regions. The information on this site should not be interpreted or used as a substitute for professional medical care. Please consult your care provider for any personal health questions or before participating in clinical trials.

Search Results

Tip

Your search for Pulmonary Disease | All Regions returned 3 studies.


Enrollment on hold Who can join A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-121/TEZ/D-IVA Combination Therapy in Subjects With Cystic Fibrosis Keywords: Cystic Fibrosis; Fibrosis; Pathologic Processes; Pancreatic Diseases; Digestive… Study Type: INTERVENTIONAL \| Region: California - Northern
Active, currently enrolling Who can join Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advance Solid Tumors Keywords: Oncology (Adult); Gastroenterology; Pulmonary Disease; APL-101-01; Advanced… Study Type: INTERVENTIONAL \| Region: California - Northern
Active, currently enrolling Who can join A Randomized, Open-label, Phase 3 Study of MK-2870 vs. Platinum Doublets in Participants With EGFR-mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors Keywords: Lung Neoplasms,; Carcinoma,; Non-Small-Cell Lung,; Respiratory Tract Neoplasms,;… Study Type: INTERVENTIONAL \| Region: California - Northern

Search Results

Saved Studies

A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-121/TEZ/D-IVA Combination Therapy in Subjects With Cystic Fibrosis

Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advance Solid Tumors

A Randomized, Open-label, Phase 3 Study of MK-2870 vs. Platinum Doublets in Participants With EGFR-mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors